Digital Breast Tomosynthesis Equipment Market By Product Type (Mammography Systems, Breast Tomosynthesis Systems, Accessories, Workstations), By Application (Breast Cancer Detection, Breast Cancer Diagnosis, Routine Screening, Diagnostic Imaging), By End-User Industry (Hospitals, Diagnostic Imaging Centers, Research Centers, Specialty Clinics), By Technology (3D Imaging, Contrast-Enhanced Tomosynthesis, Digital Mammography, Automated Breast Ultrasound), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Digital Breast Tomosynthesis Equipment Market was valued at USD 2.4 billion in 2023 and will surpass USD 6.1 billion by 2030; growing at a CAGR of 13.9% during 2024 - 2030.

The digital breast tomosynthesis (DBT) equipment market has witnessed remarkable growth in recent years, driven by advancements in imaging technologies and rising awareness about breast cancer detection. Digital breast tomosynthesis, also known as 3D mammography, offers higher accuracy in detecting breast abnormalities compared to traditional 2D mammography. This technology is gaining significant traction in both developed and developing regions due to its improved diagnostic capabilities, reduced false positives, and enhanced early detection. The market is expected to continue expanding as healthcare systems adopt more sophisticated imaging techniques to ensure better outcomes for patients, especially in the early stages of breast cancer diagnosis.

Mammography Systems Segment Is Largest Owing to Widespread Use in Screening

Mammography systems represent the largest subsegment in the digital breast tomosynthesis equipment market, owing to their longstanding use in breast cancer screening programs. Mammography is the most common method for early breast cancer detection, and its widespread adoption in hospitals, clinics, and imaging centers has solidified its dominance in the market. The technology offers a quick, non-invasive procedure for detecting lumps, masses, or any abnormal tissue changes in the breast, making it a critical tool in breast cancer prevention.

As healthcare providers increasingly adopt digital mammography systems, the overall demand for these systems continues to rise. Digital mammography offers enhanced image quality compared to traditional film mammography, leading to better interpretation and fewer call-backs for additional imaging. The growing focus on preventative healthcare and early diagnosis is expected to further increase the adoption of mammography systems, maintaining their status as the largest subsegment in the digital breast tomosynthesis market.

Breast Cancer Detection Application Is Largest Owing to Rising Incidence of Breast Cancer

The breast cancer detection application is the largest subsegment within the broader application category of digital breast tomosynthesis equipment. As the incidence of breast cancer continues to rise globally, there is an increasing need for effective and accurate diagnostic tools to detect the disease at its earliest stages. DBT significantly improves breast cancer detection rates, especially in dense breast tissue, which can be difficult to assess with conventional 2D mammography. This has made breast cancer detection a priority application for DBT technology.

The ability of digital breast tomosynthesis to generate high-resolution 3D images that can be viewed from multiple angles has made it a superior tool in detecting even the smallest tumors. Early detection allows for timely intervention, improving survival rates. As more healthcare providers recognize the benefits of DBT in breast cancer detection, the demand for these systems is expected to grow, solidifying the breast cancer detection application as the largest in the market.

Hospitals Segment Is Largest End-User Owing to High Patient Volume

Hospitals are the largest end-users of digital breast tomosynthesis equipment, primarily due to the high volume of patients they serve and their central role in providing comprehensive healthcare services. As the primary location for cancer screening and diagnosis, hospitals invest heavily in advanced diagnostic technologies like digital breast tomosynthesis to improve patient outcomes. The ability to offer early and accurate breast cancer detection is a significant driver for hospitals adopting DBT systems.

Hospitals also benefit from the integration of DBT systems into their existing imaging infrastructure, which enhances workflow and patient throughput. The growing prevalence of breast cancer and the increasing demand for advanced diagnostic tools ensure that hospitals remain the leading end-user segment in the digital breast tomosynthesis market.

3D Imaging Technology Is Fastest Growing Owing to Advancements in Imaging Precision

Among the various technologies used in digital breast tomosynthesis, 3D imaging is the fastest-growing segment. This technology allows for the creation of high-resolution, three-dimensional images of the breast, offering more detailed and accurate views of breast tissue compared to traditional 2D mammography. The ability to view the breast from different angles enhances the detection of abnormalities that may not be visible in 2D images, making 3D imaging the preferred technology for breast cancer screening.

The growing preference for 3D imaging is driven by its ability to reduce false positives and unnecessary biopsies, leading to more accurate diagnoses. Additionally, the integration of artificial intelligence (AI) with 3D imaging is further enhancing diagnostic accuracy, making it an essential tool for radiologists. As more healthcare providers adopt this advanced technology, the 3D imaging segment is expected to continue its rapid growth.

North America Is Largest Region Owing to High Adoption of Advanced Healthcare Technologies

North America dominates the digital breast tomosynthesis equipment market, driven by the high adoption rate of advanced healthcare technologies in countries like the United States and Canada. The region is home to a large number of hospitals, diagnostic imaging centers, and research institutions that are equipped with state-of-the-art diagnostic tools, including digital breast tomosynthesis systems. The strong focus on early breast cancer detection, supported by government initiatives and awareness campaigns, contributes to the high demand for DBT systems in North America.

Additionally, the presence of key market players in the region, such as Hologic, Siemens Healthineers, and GE Healthcare, further strengthens the market. The high healthcare expenditure and the availability of cutting-edge medical technologies make North America the largest regional market for digital breast tomosynthesis.

Leading Companies and Competitive Landscape

The digital breast tomosynthesis equipment market is highly competitive, with several key players leading the innovation and adoption of this technology. Major companies in the market include Hologic, Siemens Healthineers, Philips Healthcare, GE Healthcare, and Fujifilm, among others. These companies are investing heavily in research and development to improve the performance of DBT systems, focusing on enhancing image quality, reducing radiation doses, and integrating AI for better diagnostic accuracy.

In addition to technological advancements, companies are also expanding their market reach through strategic partnerships, mergers, and acquisitions. For instance, Hologic's acquisition of SuperSonic Imagine helped strengthen its portfolio of breast imaging solutions, including DBT. As the market continues to grow, competition will intensify, and companies that can offer innovative, cost-effective, and efficient solutions will have a competitive edge.

Recent Developments:

• Hologic announced the launch of its latest 3D mammography system, featuring advanced AI capabilities for faster and more accurate breast cancer detection.
• Siemens Healthineers completed the acquisition of Varian, a leader in cancer care, further strengthening its breast imaging portfolio, including digital breast tomosynthesis solutions.
• Philips Healthcare unveiled a new iteration of its digital breast tomosynthesis systems, aimed at improving diagnostic confidence and workflow efficiency.
• Fujifilm announced that its latest 3D mammography system has received FDA approval, offering enhanced image quality and lower radiation doses for breast cancer screening.
• Carestream Health entered into a strategic partnership with leading hospitals to integrate its digital breast tomosynthesis systems, enhancing early cancer detection rates.

List of Leading Companies:

• GE Healthcare
• Siemens Healthineers
• Philips Healthcare
• Hologic, Inc.
• Fujifilm Holdings Corporation
• Canon Medical Systems Corporation
• Konica Minolta, Inc.
• Carestream Health
• Agfa-Gevaert Group
• Planmed Oy
• Metaltronica S.r.l.
• Mammotome, Inc.
• Esaote S.p.A
• Mindray
• Samsung Medison

Report Scope: